

Kilitch Drugs (India) Ltd.

June 30, 2020

To, Department of Corporate Services BSE Limited P. J. Towers, Dalal Street Fort, Mumbai - 400 001 Scrip Code: BSE - 524500	To, Corporate Listing Department National Stock Exchange of India Ltd Exchange Plaza, Plot No.C-1, G Block, BKC, Bandra (E), Mumbai 400 051 Scrip Code: NSE - KILITCH
---	---

Respected Sir/Madam,

Sub: Outcome of Board Meeting - Financial Results for the quarter and year ended 31st March, 2020

We enclosed herewith the audited standalone and consolidated financial results of the Company for the quarter and year ended 31st March, 2020, which have been approved and taken on record at the meeting of the Board of Directors of the Company held today, i.e. 30th June, 2019.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), we would like to confirm that **M/s. A.M. Ghelani & Co., Chartered Accountants (Firm Registration no. 103173W)**, Statutory Auditors of the Company, have issued Audit Reports with unmodified opinion on the above financial results.

The meeting of Board of Directors held today commenced at 5:00 PM and concluded at 10:00 PM.

Kindly take the note of the above.

Thanking You,

Yours faithfully,

For: KILITCH DRUGS (INDIA) LIMITED


Mukund Mehta
Managing Director
DIN: 00147876



Encls/a



KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2020

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022-61214100, Email id: info@kilitch.com, Website: www.kilitch.com

(Rs. in Lakhs)

Sr. No.	Particulars	Three Months Ended		Year Ended	
		31/03/2020	31/12/2019	31/03/2019	31/03/2020
		Audited	Unaudited	Audited	Audited
1	Income from operations				
	Net Sales/ Income from operations	1,266.91	1,814.24	2,239.71	6,076.80
	Other Income	198.62	104.77	(6.38)	570.92
	Total Income from Operations	1,485.53	1,919.01	2,233.33	6,647.72
2	Expenses				
	(a) Cost of Materials Consumed	813.79	1,134.22	1,106.41	3,648.61
	(b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(65.00)	(56.90)	75.34	(73.48)
	(c) Employee Benefit Expenses	151.63	142.22	139.93	565.35
	(d) Finance Cost	23.03	17.02	37.91	71.59
	(e) Depreciation and Amortisation Expenses	31.27	37.80	34.01	115.30
	(f) Export Product Registration/Commission	141.77	95.51	164.65	448.15
	(g) Other Expenses	470.70	279.70	321.62	1,349.96
	Total Expenses	1,567.19	1,649.57	1,879.87	6,125.48
3	Profit / (Loss) before Exceptional Items (1-2)	(81.66)	269.44	353.46	522.24
4	Exceptional Items				
5	Profit / (Loss) from ordinary activities before tax (3+4)	(81.66)	269.44	353.46	522.24
6	Tax Expenses:				
	Current Tax	(15.87)	37.90	90.47	69.58
	Deferred Tax	(18.15)	12.95	(2.34)	6.95
7	Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)	(47.64)	218.59	265.33	445.71
8	Other Comprehensive Income (after tax)	(329.46)	83.20	61.18	(310.91)
9	Total Comprehensive Income (after taxes) (7+8)	(377.10)	301.79	326.51	134.80
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,543.42	1,543.42	1,535.52	1,543.42
11	Other Equity				
12	Earnings per share				
	(a) Basic (not annualised)	(0.31)	1.42	1.68	2.89
	(b) Diluted (not annualised)	(0.31)	1.42	1.68	2.89



Notes:

1. The above Audited Financial Results of the Company for the quarter and year ended 31st March, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 30th June, 2020.
2. The Statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
3. The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
4. This is with regards to the multiple lockdowns across the country, imposed by the Government of India on 24th March 2020 limiting the movement of entire population of the country as a preventive measure against the COVID-19 Pandemic in India. COVID -19 has severely impacted the businesses across the world.
During these unprecedented times caused by the COVID-19, a Global Pandemic as declared by WHO, the company, being a pharmaceutical manufacturing company and falling under the essential goods, has had its sole focus to ensure the uninterrupted supply of our products to meet the needs of our customers.
To help and protect its workers/employees, the company has taken extensive measures at its plant located at Navi Mumbai to limit the exposure towards the Virus by implementing social distancing norms and providing a healthy work environment at the said plant. Corporate office-based work is being conducted remotely and the Company has implemented strict travel restrictions for the employees.
The Navi Mumbai plant initially worked at a lower capacity but is now operating at its sufficient capacity. Availability of raw materials and finished stocks from third party manufacturers as well as supply chain and distribution channels were marginally impacted initially due to the lockdowns across the world. However, sufficient levels of stocks have been maintained in the channel to cater to the demand. There has been no significant adverse impact on business operations. The Company has adequate liquidity to service its obligations to its vendors and employees, as well as for payment of statutory dues.
The Management has exercised due care and made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as on and for the year ended 31st March 2020. The Company based on current estimates expects to recover the carrying amount of the above assets, net of provisions established. The Company has also assessed the impact of this whole situation on its capital and financial resources, profitability, liquidity position, internal financial controls etc., and is of the view that based on its present assessment, this situation does not materially impact these financial results.
In view of the uncertainties regarding its nature and duration of the current COVID-19 Pandemic, we are unable to predict the future impact on our business operations. However, The Company will continue to closely monitor the situation and take appropriate measures in an attempt to mitigate any adverse impact on its future economic conditions.
5. The figures for the quarter ended 31st March, 2020 and 31st March, 2019 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2020 and 31st March, 2019 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.
6. The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.

Place : Mumbai
Dated: 30th June, 2020



For and on behalf of the Statutory Auditors


Mukund P. Mehta
Managing Director



KILITCH DRUGS (INDIA) LIMITED

Balance Sheet
As at 31st March, 2020

Particulars	(Rs.in Lakhs)	
	As at 31st March, 2020	As at 31st March, 2019
ASSETS		
Non-current assets		
- Property, Plant and Equipment	761.63	778.91
- Capital work-in-progress	-	-
- Other Intangible Assets	5.02	2.90
Financial assets		
- Investments	7,026.51	7,123.66
- Loans/Advances	3,866.31	2,772.80
- Other Financial Assets	53.83	-
Deferred tax assets (Net)	96.18	103.13
(A)	11,809.48	10,781.40
Current Assets		
- Inventories	555.67	471.58
Financial assets		
- Investments	2,781.04	2,841.62
- Trade Receivables	1,700.58	2,314.53
- Cash & Cash Equivalents	272.26	407.21
- Other Financial Assets	2.54	11.04
Other Current Assets	289.69	375.43
(B)	5,601.78	6,421.41
TOTAL ASSETS (A + B)	17,411.26	17,202.81
EQUITY AND LIABILITIES		
Equity		
- Equity Share Capital	1,543.42	1,535.52
- Other Equity	13,621.29	13,572.84
Equity attributable to Owner	15,164.71	15,108.36
(A)	15,164.71	15,108.36
Non-Current liabilities		
- Provisions	38.80	41.34
Current liabilities		
Financial Liabilities		
- Borrowings	1,251.22	935.71
- Trade Payables		
Micro and Small Enterprises		
Others	790.63	546.90
- Other Financial Liabilities	2.07	88.07
Provisions	87.41	68.15
Current Tax Liabilities [Net]	16.24	171.83
Other Current Liabilities	60.18	242.45
(B)	2,246.55	2,094.45
TOTAL LIABILITIES (A + B)	17,411.26	17,202.81



For and on behalf of the Board of Directors

Mukund P. Mehta
Managing Director




Place : Mumbai
Dated: 30th June, 2020

KILITCH DRUGS (INDIA) LIMITED

Cash Flow Statement For the year ended 31st March 2020

Particulars	Year Ended 31st March 2020		Year Ended 31st March 2019	
	[Rs.]	[Rs.]	[Rs.]	[Rs.]
(Rs. in Lakhs)				
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items and tax		522.23		1,952.48
<u>Adjustments for:</u>				
Depreciation and amortisation	115.30		120.38	
Interest income	(195.69)		(75.69)	
Dividend income	(10.92)		(23.94)	
(Profit)/Loss on sale of Investments	(181.94)		(240.71)	
Sundry Balances written back	(9.06)		(17.51)	
Provision for Gratuity & Leave Encashment	10.83		13.15	
Employee Stocks Option Cost	6.68			
Bad Debts / Provision for Doubtful Debts	(42.83)		(126.06)	
(Profit) / Loss from Investment in Partnership Firm	0.24		0.27	
Net unrealised exchange (gain) / loss	(132.30)	(439.68)	69.02	(281.09)
Operating profit / (loss) before working capital changes		82.55		1,671.39
<u>Changes in working capital:</u>				
<u>Operating Assets:</u>				
Inventories	(84.09)		(191.94)	
Trade receivables	789.11		(185.48)	
Other current assets	85.74		9.21	
Deposits & advances	(1.76)		(11.53)	
Other financial assets	8.50		19.87	
<u>Operating Liabilities:</u>				
Trade payables	252.79		(201.52)	
Other current liabilities	(182.27)		42.36	
Provisions	3.37	871.39	6.89	(512.14)
Gross cash flow from / (used in) operating activities		953.94		1,159.25
Direct Taxes (Paid) / refunded		(225.17)		(417.65)
Net cash flow from / (used in) operating activities (A)		728.77		741.60
B. CASH FLOW FROM INVESTING ACTIVITIES				
Fixed assets purchased	(100.14)		(167.02)	
Loans/Advances to related Parties	(1,091.74)		(2,402.48)	
Proceeds (Net) from the sale of Current investments	(65.86)		299.96	
Proceeds (Net) from the sale of long-term investments	96.91		(99.40)	
Movement in other Bank balance	(53.83)		78.97	
Interest received	195.69		75.69	
Dividend received	10.92		23.94	
		(1,008.07)		(2,190.36)
		(1,008.07)		(2,190.36)
Net cash flow from / (used in) investing activities (B)		(1,008.07)		(2,190.36)



C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Shares Issued (Incl. ESOPs)	7.89		24.50
Proceeds from Borrowings (Net of Repayments)	315.50		853.24
Money received against warrants	-		685.84
Dividends paid (Inclusive of tax on Dividend)	(179.03)		(95.04)
Net cash flow from / (used in) financing activities (C)		144.36	1,468.55
Net increase / (decrease) In Cash and cash equivalents (A+B+C)		† (134.94)	19.78
Cash and cash equivalents at the beginning of the year		407.21	387.43
Cash and cash equivalents at the end of the year		272.27	407.21
Cash and cash equivalents at the end of the year *			
* Comprises:			
(a) Cash on hand		0.63	45.16
(b) Balances with banks			
(i) In current accounts		269.57	273.98
(ii) In earmarked accounts		2.07	88.07
		272.27	407.21

For and on behalf of the Board of Directors

Mukund P. Mehta
Managing Director



Place : Mumbai
Dated: 30th June, 2020



A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

Independent Auditor's Report on Quarterly and Year to Date Audited Standalone Financial Results of Kilitch Drugs (India) Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended)

To,
The Board of Directors of
Kilitch Drugs (India) Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying Statement of quarterly and year to date Standalone Financial Results of Kilitch Drugs (India) Limited ("the Company") for the quarter and year ended March 31, 2020 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- i. is presented in accordance with requirements of the Listing Regulations in this regard; and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit, other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2020.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, (as amended) ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us is sufficient and appropriate to provide a basis for our opinion.



Emphasis of Matter

We draw attention to Note 4 of the Results Statement, which states the impact of Corona virus Disease 2019 (Covid-19) on the operations of the Company. Our opinion is not modified in respect of this matter

Management's Responsibility for the Standalone Financial Results

The statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the accounting standards specified under section 133 of the Act, read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provision of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statements, Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statements as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered



A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to Financial Statement in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.




A. M. GHELANI & COMPANY
CHARTERED ACCOUNTANTS

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The statement includes the results for the quarter ended March 31, 2020 being the balancing figure between the audited figures in respect of full financial year ended March 31, 2020 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For A. M. Ghelani & Company
Chartered Accountants
Firm Registration No. 103173W



Chintan A. Ghelani
Partner

Membership No. 104391



ICAI UDIN: 20104391AAAABK1732

Place : Mumbai

Date : 30th June, 2020

KILITCH DRUGS (INDIA) LIMITED
STATEMENT OF CONSOLIDATED AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2020

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701
Tel No: 022- 61214100, Email Id: Info@kilitch.com, Website: www.kilitch.com

(Rs. in Lakhs)

Sr. No.	Particulars	CONSOLIDATED				
		Three Months Ended			Year Ended	
		31/03/2020	31/12/2019	31/03/2019	31/03/2020	31/03/2019
		Audited	Unaudited	Audited	Audited	Audited
1	Income From Operations					
	Net Sales/Income from Operations	1,162.31	1,592.99	1,916.65	5,332.00	8,248.99
	Other Income	147.16	68.97	(62.17)	412.55	400.40
	Total Income from Operations	1,309.47	1,661.96	1,854.48	5,744.55	8,649.39
2	Expenses					
	Cost of Materials Consumed	681.23	853.04	915.40	2,982.03	4,834.51
	Variation in inventories of finished goods, work-in-progress and Stock-in-Trade	(65.00)	58.81	75.35	(73.48)	(17.70)
	Employee Benefit Expenses	152.58	143.13	140.88	569.01	528.37
	Finance Cost	23.03	17.02	37.91	71.59	37.91
	Depreciation and Amortisation Expenses	52.43	58.76	55.19	199.90	205.11
	Export Product Registration/Commission	141.77	95.51	164.65	448.15	683.93
	Other expenses	482.17	290.40	327.44	1,386.62	1,518.60
	Total Expenses	1,468.21	1,516.67	1,716.82	5,583.82	7,790.73
3	Profit/(Loss) before Exceptional items (1-2)	(158.74)	145.29	137.66	160.73	858.66
4	Exceptional Items					
5	Profit/(Loss) from ordinary activities before tax (3+4)	(158.74)	145.29	137.66	160.73	858.66
6	Less : Tax Expenses					
	Current Income Tax	(15.87)	37.90	90.47	69.58	424.08
	Deferred Tax	(18.15)	12.89	(2.40)	6.95	51.60
7	Profit/(Loss) after tax for the period from continuing operations (5-6)	(124.72)	94.50	49.59	84.20	382.98
8	Other Comprehensive Income (after Tax)	(329.46)	83.20	61.19	(310.91)	(105.69)
9	Total Comprehensive Income (after taxes) (7+8)	(454.18)	177.70	110.78	(226.71)	277.29
10	Net Profit / (Loss) attributable to					
	a) Owner of the Company	(124.72)	94.50	49.59	84.20	382.98
	b) Non Controlling interest	-	-	-	-	-
11	Other Comprehensive Income attributable to					
	a) Owner of the Company	(329.46)	83.20	61.19	(310.91)	(105.69)
	b) Non Controlling interest	-	-	-	-	-
12	Total Income attributable to					
	a) Owner of the Company	(454.17)	177.70	110.78	(226.71)	277.29
	b) Non Controlling interest	-	-	-	-	-
13	Paid-Up equity share capital (Face Value Rs. 10 per share)	1,543.42	1,543.42	1,535.52	1,543.42	1,535.52
14	Other Equity				10,281.84	10,570.21
15	Earning per share					
	(a) Basic (not annualised)	(0.81)	0.62	0.30	0.55	2.61
	(b) Diluted (not annualised)	(0.81)	0.62	0.30	0.55	2.61



Notes:

1. The above Audited Consolidated Financial Results for the quarter and year ended 31st March, 2020 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 30th June, 2020.
2. The statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable..
3. The Group is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS 108.
4. This is with regards to the multiple lockdowns across the country, imposed by the Government of India on 24th March 2020 limiting the movement of entire population of the country as a preventive measure against the COVID-19 Pandemic in India, COVID -19 has severely impacted the businesses across the world.
During these unprecedented times caused by the COVID-19, a Global Pandemic as declared by WHO, the group, being in the pharmaceutical industry and falling under the essential goods, has had its sole focus to ensure the uninterrupted supply of our products to meet the needs of our customers.
To help and protect its workers/employees, the Group has taken extensive measures at its plant located at Navi Mumbai to limit the exposure towards the Virus by implementing social distancing norms and providing a healthy work environment at the said plant. Corporate office-based work is being conducted remotely and the Group has implemented strict travel restrictions for the employees.
The Navi Mumbai plant initially worked at a lower capacity but is now operating at its sufficient capacity. Availability of raw materials and finished stocks from third party manufacturers as well as supply chain and distribution channels were marginally impacted initially due to the lockdowns across the world. However, sufficient levels of stocks have been maintained in the channel to cater to the demand. There has been no significant adverse impact on business operations. The Group has adequate liquidity to service its obligations to its vendors and employees, as well as for payment of statutory dues.
The Management has exercised due care and made reasonable judgements and estimates from internal and external sources of information including economic forecasts, inter alia, in determining carrying amounts of trade receivables, property, plant & equipment, inventories and other financial assets while preparing the financial results as on and for the year ended 31st March 2020. The Group based on current estimates expects to recover the carrying amount of the above assets, net of provisions established. The Group has also assessed the impact of this whole situation on its capital and financial resources, profitability, liquidity position, internal financial controls etc., and is of the view that based on its present assessment, this situation does not materially impact these financial results.
In view of the uncertainties regarding its nature and duration of the current COVID-19 Pandemic, we are unable to predict the future impact on .
The figures for the quarter ended 31st March, 2020 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2020 and unaudited published year to date figures upto the nine months of the relevant financial year which were subject to limited review by the Statutory Auditors.
5. The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.
- 6.

Place:
Date:

Mumbai
30th June, 2020



For and on behalf of the Board of Directors

Mukund P. Mehra
Director




KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES AS AT 31st MARCH, 2020
CIN:L24239MH1992PLC066718


(Rs. In Lacs)

Particulars	As at 31st March, 2020	As at 31st March, 2019
ASSETS		
Non-current assets		
Property, plant and Equipment	873.23	851.21
Capital work-in-progress	2,960.14	2,025.28
Other Intangible assets	2,279.89	2,362.03
Financial assets		
- Investments	2,404.81	2,501.96
- Loans/Advances	36.02	34.26
- Other Financials Assets	53.83	-
Deferred tax assets (Net)	96.62	103.57
(A)	8,704.54	7,878.31
Current assets		
Inventories	555.67	471.58
Financial assets		
- Investments	2,781.04	2,841.62
- Trade and other receivables	1,585.89	1,943.59
- Cash and cash equivalents	279.66	794.01
- Other Financials Assets	66.15	56.00
Other current assets	310.15	381.03
(B)	5,578.56	6,487.83
TOTAL ASSETS (A + B)	14,283.10	14,366.14
Equity		
Equity Share capital	1,543.42	1,535.52
Other equity	10,281.84	10,570.21
Equity attributable to the owners	11,825.26	12,105.73
Non-controlling interest	221.83	209.66
(A)	12,047.09	12,315.39
Liabilities		
Non - Current Liabilities		
Provisions	38.80	41.34
Current liabilities		
Financial liabilities		
- Borrowings	-1,260.92	945.41
- Trade Payables		
Micro and Small Enterprises		
Others	710.38	434.63
- Other financial liabilities	3.50	88.07
Provisions	87.77	68.50
Current tax Liabilities (Net)	16.24	171.83
Other current liabilities	118.40	300.97
(B)	2,236.01	2,050.75
TOTAL LIABILITIES (A+B)	14,283.10	14,366.14

For and on behalf of the Board of Directors


Mukund P. Mehta
 Managing Director

Place : Mumbai
Dated: 30th June, 2020



KILITCH DRUGS (INDIA) LIMITED
CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED ON MARCH 31, 2020

Rs. (In Lacs)

Particulars	For the Year ended 31st March 2020		For the Year ended 31st March 2019	
	[Rs.]	[Rs.]	[Rs.]	[Rs.]
A. CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit / (Loss) before extraordinary items and tax Adjustments for:		160.73	205.11	858.67
Depreciation and amortisation			(16.36)	
Interest income	199.90		(23.94)	
Dividend income	(16.42)		(240.71)	
(Profit)/Loss on sale of Investments	(10.92)		0.27	
Share of (Profit)/ Loss from Partnership Firm	(181.94)		(17.51)	
Sundry Balances written back	0.24		380.50	
Bad debts written off	(9.06)		13.20	
Provision for Gratuity & Leave Encashment	10.86		0.07	
Loss/(Profit) from Sale of assets			12.24	
Loss/(Profit) from Trading in Securities			(126.06)	
Employee Stocks Option cost	6.68		(0.24)	
Bad Debts / Provision for Doubtful Debts	(42.68)			
Net unrealised exchange (gain) / loss	(150.90)			
Operating profit / (loss) before working capital changes		(194.22)		186.57
Changes in working capital:		(33.49)		1,045.24
Operating Assets:				
Inventories	(84.09)		(191.94)	
Trade receivables	551.28		(128.30)	
Other financial Assets	(10.14)		(3.59)	
Other current assets	70.88		9.00	
Deposits/Advances	(1.76)		(12.71)	
Operating Liabilities:				
Trade payables	284.82		(319.41)	
Other financial liabilities	1.43		41.60	
Other current liabilities	(182.57)		6.84	
Provisions	3.34			(598.52)
Gross cash flow from / (used in) operating activities		633.17		
Direct Taxes (Paid) / refunded		599.68		446.72
		(225.17)		(417.63)
Net cash flow from / (used in) operating activities		374.51		29.09
B. CASH FLOW FROM INVESTING ACTIVITIES				
Capital expenditure on fixed assets, including capital advances	(1,049.93)		(1,902.17)	
Proceeds (Net) from the sale of Current investments	(65.87)		287.73	
Proceeds (Net) from the sale of Non-Current investments	96.91		97.33	
Movement in other Bank balance	(53.83)		78.97	
Interest received	16.42		16.36	
Dividend received	10.92		23.94	
		(1,045.40)		(1,397.86)
Net cash flow from / (used in) investing activities (B)		(1,045.40)		(1,397.86)




DECLARATION

[Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015]

Pursuant to the requirement as specified by Regulation 33 Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended by SEBI (Listing Obligation and Disclosure Requirements) (Amendment) Regulations, 2016 it is hereby declared by the Auditors Report for the financial year ended as on March 31, 2020 contains unmodified opinion as provided under the Independent Auditors' Report which is attached herewith for your reference.

You are kindly requested to take the above declaration in your records.

For: KILITCH DRUGS (INDIA) LIMITED



Mukund Mehta
Managing Director
DIN: 00147876



Date: 30th June 2020